Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a tablet for oral use. It is employed to medically terminate early intrauterine pregnancy under clinical supervision. The drug works by blocking progesterone, a hormone essential for maintaining the uterine lining, thereby facilitating embryo detachment and uterine expulsion.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across multiple regions.

Mifegyne (mifepristone) is used in the medical management of early intrauterine pregnancy termination.

Early intrauterine pregnancy termination: induces abortion in pregnancies up to 10 weeks gestation by disrupting progesterone support. Combination regimen with misoprostol: enhances uterine expulsion when used sequentially after mifepristone.

Mifegyne may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea or vomiting - Abdominal or pelvic pain - Vaginal bleeding or spotting - Fatigue or headache - Diarrhea or constipation - Dizziness or mild fever

Serious or Rare Side Effects: - Severe hemorrhage requiring medical intervention - Infection or sepsis following incomplete abortion - Allergic reaction including rash, swelling, or anaphylaxis - Liver injury or elevated hepatic enzymes - Uterine rupture (very rare)

Prior to prescribing Mifegyne, clinicians should observe several safety considerations.

Confirm gestational age: ensure pregnancy is ≤10 weeks. Screen for ectopic pregnancy: rule out non‑intrauterine gestation. Assess contraindications: avoid in chronic adrenal insufficiency, anticoagulant therapy, or severe anemia. Monitor vital signs: observe for excessive bleeding or infection after administration. Store at ambient temperature: keep below 25 °C in original packaging, protected from moisture.

Mifegyne can interact with other medicines that affect its metabolism or hemostasis.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase drug exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may heighten bleeding risk. - Corticosteroids: may mask adrenal insufficiency symptoms. - Hormonal contraceptives: may have reduced effectiveness when used concurrently. - Antifungal azoles (e.g., fluconazole): may modestly increase serum levels.